Skip to main content

Table 1 Summary of patient demographics and clinical/biochemical characteristice (n = 112). All data are expressed as mean (SEM) and number (percentages).

From: The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis

  Reference ranges
Age (years) 68.4 ± 0.87  
Age at menopause (years) 46.6 ± 0.56  
BMI (kg/m 2) 24.2 ± 0.43  
Current smokers (%) 21 (18.6)  
Alcohol intake ≤ 14 units/week (%) 52 (46.4)  
Previous fragility Fracture (s) (%) 68 (60.7)  
Family history of osteoporosis (%) 27 (24.1)  
Family history of fracture (%) 20 (17.9)  
History of falls (%) 31 (27.7)  
Formal exercise (%) 37 (33.0)  
Walking (≥ 30 minutes/day) (%) 26 (50.9)  
Bisphosphonate treatment duration (years) 3.81 ± 0.28  
Serum Calcium (nmol/l) 2.43 ± 0.01 2.2–2.6
Serum 25(OH) vitamin D (nmol/l) 70.6 ± 2.86 40–195
Serum Parathyroid Hormone (ng/l) 51.6 ± 3.12 10–65
Urine CTX (μg/mmol creatinine) 151.3 ± 16.43 45–1035